Infliximab Therapy in Steroid-Refractory Ulcerative Colitis

Medical Necessity and Standard of Care

The American Gastroenterological Association (AGA) recommends infliximab as a preferred first-line biologic therapy in biologic-naïve patients with moderate-severe ulcerative colitis, with strong evidence supporting its use in patients who have failed conventional therapy 1, 2
The AGA guidelines suggest that biologic agents should be used early in patients with moderate-severe disease at high risk of colectomy, rather than gradual step-up therapy 1, 5
Infliximab is recommended as rescue therapy for patients refractory to intravenous corticosteroids, with standard dosing at weeks 0, 2, and 6, according to the 2016 consensus statement 3, 6
The Toronto Consensus 2015 provides a strong recommendation (high-quality evidence) for anti-TNF therapy in patients who fail to respond to corticosteroids 7

The proposed 10mg/kg dosing of infliximab has biological rationale and observational evidence supporting its use in severe, steroid-refractory disease, although guidelines cannot make a definitive recommendation due to limited evidence quality 4, 8, 9
The AGA 2020 guidelines acknowledge that patients with low body weight, high inflammatory burden, or low albumin may need higher dosing (10mg/kg) or shorter intervals 4
Observational data shows that upfront induction with 10mg/kg was superior to dose stacking with 5mg/kg, with lower colectomy risk (RR 0.24; 95% CI 0.08-0.68) 10, 8

The 2020 AGA guidelines support infliximab for both induction and maintenance of remission in moderate-severe ulcerative colitis 1, 5
Continuation of infliximab every 8 weeks after induction is standard of care for maintaining remission 1, 2

Real-world effectiveness data demonstrates that infliximab prevents colectomy and achieves steroid-free remission in patients with steroid-refractory ulcerative colitis, with clinical remission rates of 30% sustained to week 54, and corticosteroid-free remission rates of 22% 11